Nuwellis Inc vs Plby Group Inc — how do they compare? Nuwellis Inc trades at $2.94 (market cap $1.09M), while Plby Group Inc trades at $1.21 (market cap $139.87M). The key difference: Plby Group Inc is far larger — about 128.3× Nuwellis Inc's market cap. Which is the better fit depends on your goals.
| NUWE | PLBY | |
|---|---|---|
Market Cap | $1.09M | $139.87M |
Sector | Technology | Consumer Cyclical |
52-Week High | $527.46 | $2.71 |
52-Week Low | $2.80 | $1.11 |
Enterprise Value | -$722.58K | $287.68M |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% over 24 hours, following a recent 35:1 reverse stock split effective June 26, 2026. The stock shows a bearish technical signal with all moving averages indicating sell. Fundamentally, the company reported a net loss of $17.52M in 2025, with negative profit margins, though revenue grew to $8.27M. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and new patents offer growth potential. Key risks include negative ROE, reliance on financing, and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid financial headwinds.
PLBY Group trades at $1.23, up 5.13% today, amid a bearish technical signal. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable. Recent developments include inclusion in the Russell 2000 and 3000 indices and a major share repurchase. Analyst consensus is strongly bullish with 75% buy ratings, reflecting optimism around the company's strategic focus on licensing, media, and experiences.
The outlook for PLBY hinges on sustaining its operational turnaround and achieving profitability. Key opportunities include brand monetization and cost management, while risks involve high debt levels and competitive pressures. Investors should weigh the strong analyst support against the company's historical losses and current negative equity position.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →